Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026 ...

Eli Lilly LLY, a dominant player in the global obesity market, derives most of its revenues from its blockbuster GLP-1 medicines, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Despite ...